0001144204-16-116981.txt : 20160805
0001144204-16-116981.hdr.sgml : 20160805
20160805193034
ACCESSION NUMBER: 0001144204-16-116981
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160803
FILED AS OF DATE: 20160805
DATE AS OF CHANGE: 20160805
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Spark Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609351
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 462654405
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: 888-772-7560
MAIL ADDRESS:
STREET 1: 3737 MARKET STREET
STREET 2: SUITE 1300
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mehra Anand
CENTRAL INDEX KEY: 0001590102
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36819
FILM NUMBER: 161812316
MAIL ADDRESS:
STREET 1: 3000 SAND HILL ROAD, 4-250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
v446222_4.xml
OWNERSHIP DOCUMENT
X0306
4
2016-08-03
0
0001609351
Spark Therapeutics, Inc.
ONCE
0001590102
Mehra Anand
SOFINNOVA VENTURES
3000 SAND HILL ROAD, 4-250
MENLO PARK
CA
94025
1
0
0
0
Common Stock
2016-08-03
4
S
0
4612
60
D
1407689
I
See footnote
Common Stock
2016-08-04
4
S
0
452
60
D
1407237
I
See footnote
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Venture Partners VIII, L.P. ("SVP VIII") on October 8, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.02, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The securities are owned directly by SVP VIII. Sofinnova Management VIII, L.L.C. ("SM VIII"), the general partner of SVP VIII, and Anand Mehra, a director of the Issuer, James I. Healy, and Michael Powell, the managing members of SM VIII, may be deemed to have shared voting and dispositive power over the shares owned by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein.
/s/ Nathalie Auber, attorney-in-fact for Anand Mehra
2016-08-05